TransCode Therapeutics Statistics

Total Valuation

RNAZ has a market cap or net worth of $6.64 million. The enterprise value is $4.84 million.

Market Cap	6.64M
Enterprise Value	4.84M

Important Dates

The last earnings date was Thursday, November 14, 2024, after market close.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	n/a

Share Statistics

RNAZ has 17.27 million shares outstanding. The number of shares has increased by 18,942.25% in one year.

Current Share Class	17.27M
Shares Outstanding	17.27M
Shares Change (YoY)	+18,942.25%
Shares Change (QoQ)	+108.26%
Owned by Insiders (%)	0.04%
Owned by Institutions (%)	1.89%
Float	17.26M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.97
P/TBV Ratio	4.02
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.09.

Current Ratio	1.58
Quick Ratio	0.82
Debt / Equity	0.09
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-245.75

Financial Efficiency

Return on equity (ROE) is -490.03% and return on invested capital (ROIC) is -267.73%.

Return on Equity (ROE)	-490.03%
Return on Assets (ROA)	-129.28%
Return on Capital (ROIC)	-267.73%
Revenue Per Employee	n/a
Profits Per Employee	-$1.49M
Employee Count	10
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -95.83% in the last 52 weeks. The beta is 0.65, so RNAZ's price volatility has been lower than the market average.

Beta (5Y)	0.65
52-Week Price Change	-95.83%
50-Day Moving Average	0.50
200-Day Moving Average	0.66
Relative Strength Index (RSI)	41.52
Average Volume (20 Days)	444,228

Short Selling Information

The latest short interest is 743,584, so 4.31% of the outstanding shares have been sold short.

Short Interest	743,584
Short Previous Month	1.22M
Short % of Shares Out	4.31%
Short % of Float	4.31%
Short Ratio (days to cover)	0.50

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-14.65M
Pretax Income	-17.06M
Net Income	-14.93M
EBITDA	-14.54M
EBIT	-14.65M
Earnings Per Share (EPS)	-$2.17

Full Income Statement

Balance Sheet

The company has $1.88 million in cash and $152,481 in debt, giving a net cash position of $1.72 million or $0.10 per share.

Cash & Cash Equivalents	1.88M
Total Debt	152,481
Net Cash	1.72M
Net Cash Per Share	$0.10
Equity (Book Value)	1.65M
Book Value Per Share	0.10
Working Capital	1.33M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$15.85 million and capital expenditures -$21,261, giving a free cash flow of -$15.87 million.

Operating Cash Flow	-15.85M
Capital Expenditures	-21,261
Free Cash Flow	-15.87M
FCF Per Share	-$0.92

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

RNAZ does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18,942.25%
Shareholder Yield	-18,942.25%
Earnings Yield	-224.84%
FCF Yield	-239.12%

Analyst Forecast

The average price target for RNAZ is $3.00, which is 680.23% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$3.00
Price Target Difference	680.23%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-31.25%

Stock Forecasts

Stock Splits

The last stock split was on January 16, 2024. It was a reverse split with a ratio of 0.025:1.

Last Split Date	Jan 16, 2024
Split Type	Reverse
Split Ratio	0.025:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a